期刊文献+

A型肉毒毒素治疗雷诺现象一例 被引量:4

原文传递
导出
摘要 临床资料患者,女,53岁,因"双手遇冷变白发紫2年,手指皮肤紧绷半年"于2012年11月8日入院.患者入院前2年出现双手指1~5、双足趾1~5遇冷后变白、发紫,遇热后可缓解;入院前1年开始出现全身多处关节疼痛,主要累及双肩、双肘、双腕、双手l~5掌指关节、l~5近端指间关节、右膝,伴有腰部酸痛;入院前半年出现双手指皮肤肿胀、紧绷感觉,双侧足趾1~5有类似症状,夏天症状不缓解,冬天伴有严重冻疮.病程中有长期反复口腔溃疡、口眼干、多发龋齿.入院体检:双手、双足肢端皮温明显降低,双侧手指1~5、手背、前臂前四分之一、双足背皮肤变硬并增厚,双侧腕关节压痛,双手l~5近端指间关节、1~5掌指关节肿胀并压痛.
出处 《中华神经科杂志》 CAS CSCD 北大核心 2013年第9期646-647,共2页 Chinese Journal of Neurology
基金 国家自然科学基金资助项目(81000481) 中国医学基金会资助项目(GJYX1201)
  • 相关文献

参考文献9

  • 1Herrick AL. Treatment of Raynaud' s phenomenon: new insights and developments. Curt Rheumatol Rep,2003 ,5 :168-174.
  • 2I,evien TL. Advances in the treatment of Raynaud' s phenomenon. Vase Heahh Risk Manag,2010,6 : 167-177.
  • 3Sycha T, Graninger M, Auff E, et al. Botulinum toxin in the treatment of Raynaud' s phenomenon: a pilot study. Eur J Clin ln,,,est ,2004,34 :312-313.
  • 4van Beek AL,l,im PK,Gear AJ, et al. Management of vasospastic disorders with botulinumm toxin A. Plast Reconstr Surg,2007,119: 217-226.
  • 5Fregene A, Ditmars D, Siddiqui A. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud ' s phenomenon. J Hand Surg,2009,34A :446:1-52.
  • 6Neumeister MW, Chambers CB, llerron MS, et al. Botox therapy fbr ischemic digits. Plast Reconstr Surg,2009,124 : 191-201.
  • 7Neumeister MW. Botulinnm toxin type A in the treatment of Raynand' s phenomenon. J Iland Surg Am,2010,35:2085-2092.
  • 8MatieDB,I.ee TY,Wells RG,et al. The effeets of botulinum toxin lype A on muscle blood perfusion and metabolism. Plast Reeonstr St rg, 2007,120:1823-1833.
  • 9Morris JL, Jobling P, Gibbins IL. Difierential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilalor neurons. Am J Physiol Heart Circ Physiol,2001,281 : H2124-2132.

同被引文献56

  • 1Coveliers HM,Hoexum F, Nederhoed JH, et al. Thoracicsympathectomy for digital ischemia: a summary of evxdence[J].J Vase Surg, 2011,54(1): 273-277.
  • 2Herrick AL. Pathogenesis of Raynaud's phenomenonfj].Rheumatology, 2005, 44(5): 587-596.
  • 3Tzilalis V, Panagiotopoulos N,Papatheodorou G, et ai. Preva-lence of Raynaud,s phenomenon in young Greek males[J]. ClinRheumatol, 2011,30(1): 57-59.
  • 4Maricq HR, Carpentier PH, Weinrich MC,et al. Geographicvariation in the prevalence of Raynaud's phenomenon: a 5 regioncomparison[J]. J Rheumatol, 1997, 24(5): 879-889.
  • 5Levien TL. Advances in the treatment of Raynaud, s phenomenon[J]. Vase Health Risk Manag, 2010, 6: 167-177.
  • 6Serri J, Legr6 R,Veit V, et al. Botulinum toxin type A con-tribution in the treatment of Raynaudf s phenomenon due tosystemic sclerosis[J]. Ann Chir Plast Esthet,2011,58(6): 658-662.
  • 7Jenkins SN, Neyman KM, Veledar E? et al. A pilot studyevaluating the efficacy of botulinum toxin A in the treatment ofRaynaud phenomenon[J]. J Am Acad Dermatol? 2013,69(5):834-835.
  • 8Fregene A, Ditmars D, Siddiqui A. Botulinum toxin type A: atreatment option for digital ischemia in patients with Raynaud'sphenomenon[J]. J Hand Surg Am, 2009 , 34A(3): 446-452.
  • 9Neumeister MW. Botulinum toxin type A in the treatment ofRaynaud's phenomenon[J]. J Hand Surg Am, 2010, 35(12):2085-2092.
  • 10Van Beek AL, Lim PK? Gear AJ, et al. Management of va-sospastic disorders with botulinum toxin A [J]. Plast ReconstrSurg, 2007,119(1):217-226.

引证文献4

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部